GSK Dives Into Neurology With £30m Oxford University Pact
Partners Launch Molecular And Computational Medicine Institute
After returning to the neuroscience space in the summer through a big-money deal with Alector, GlaxoSmithKline is setting up an institute with the University of Oxford that will target neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, frontal temporal dementia, ALS and pain.
You may also be interested in...
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
The German major is investing heavily in cancer R&D and has opened the doors of a new facility in the biotech epicenter on the east coast of the US.
The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of the Stockholm-based firm's compound, which is also being evaluated for lung cancer.